Compare Davita Inc (DVA) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Moody's Corporation — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Moody's Corporation trades at $458.7 (market cap $79.44B). The key difference: Moody's Corporation is far larger — about 7× Davita Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Moody's Corporation for 132 Days on average.
| DVA | MCO | |
|---|---|---|
Market Cap | $11.29B | $79.44B |
Volume | 582,204 | 526,684 |
Sector | Health | Financials |
52-Week High | $240.96 | $539.61 |
52-Week Low | $103.87 | $412.23 |
Typical Hold Time | 113 Days | 132 Days |
Enterprise Value | $24.01B | $85.46B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Moody's Corporation (MCO) trades at $449.63, down 0.59% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, while net income margins expanded to 34.25%. Recent developments include strategic partnerships and board appointments, supporting the company's market leadership in credit analytics.
The investment outlook is positive given Moody's robust profitability, high ROE of 80.15%, and analyst consensus price target of $536.40 (19% upside). Risks include high valuation multiples (P/E 28.53, P/S 9.79) and exposure to economic cycles affecting credit demand. Institutional sentiment remains bullish with 56% buy ratings, though technical indicators suggest near-term consolidation near support at $440.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
